CREBBP and hematologic disorder: CCS1477 compound, a selective and orally bioavailable inhibitor of the bromodomain of p300 and CBP is being evaluated for its safety and efficacy in two clinical trials in hematological malignancies (NCT04068597) and in castration-resistant prostate cancer and other solid tumors (NCT03568656), both still in the recruitment phase.